Astellas' Smyraf, which has drawn attention as a treatment for rheumatoid arthritis, withdrew the license in a year.

Smyraf is the third domestically licensed inhibitor of Januskinase (JAK) after Xeljanz (Tofacitinib, Pfizer) and Olumiant (Baricitinib, Lilly). However, it failed to complete the registration process and withdrew from the Korean market.

The MFDS announced on the 31st that the permits of Smyraf 100mg and Smyraf 50mg from Astellas Korea have been revoked.

Smyraf was licensed in January last year as a new drug for rheumatoid arthritis. In particular, although existing rheumatoid arthritis treatments had the disadvantage of injection type, this product was highly